SirTlab Corporation Overview
SirTLab is the leader in Restoring SIRT6 Expression for Severe Liver Diseases and Diseases of Aging. Sirtuin 6 (SIRT6) is a Key Regulator for Health in all cells. Levels of SIRT6 are reduced in liver diseases: NASH1, other cirrhosis, metabolic syndrome, acetaminophen toxicity. SIRTLab patented SIRT6-mRNA-LNP2 for liver specific expression of SIRT6 is based on 18 years of research.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
SIRTLab Corporation Appoints Michael G. Kauffman, MD, PhD, as Co-Chairman of the Board of Directors and Chief Medical Officer
SIRTLab Corporation has appointed Michael G. Kauffman as Co-Chairman of the Board of Directors and Chief Medical Officer. Dr. Kauffman has a background in the biotechnology industry and has made major contributions to the approvals of three cancer drugs. SIRTLab focuses on the manipulation of sirtuin proteins for the treatment of severe liver diseases and longevity. Their lead program is centered around sirtuin 6 (SIRT6), which has shown promising results in restoring energy homeostasis, improving metabolic profiles, and prolonging lifespan in mice. The company aims to develop agents for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. The appointment of Dr. Kauffman is seen as a significant advancement for SIRTLab as they prepare to advance their novel class of agents.
Management Changes
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $1.53M |
| Last funding | $485.76K |
| Stage | Seed |
| Rounds | 3 |
| Investors | 1 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | www.sirtlabcorp.com/ |
Locations
Ramat Gan, Israel
Photos & Videos
No files yet
